🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

Recruitingn/aAges 18 Years - anyAllAssistance Publique - Hôpitaux de Paris
NCT02828202 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Prevention of melanoma can be efficient but mortality remains unchanged and 15 to 20% of patients still die from melanoma. Indeed metastatic melanoma is a heterogeneous highly and multiple mutations driven cancer. Significant survival benefit was demonstrated since 2011 with anti-CTLA4 +/- programmed death-1 (anti PD1) antibodies, B-Raf proto-oncogene, serine/threonine kinase (BRAF) and MAP-ERK kinase (MEK) inhibitors. Future improvement of advanced melanoma prognosis will rely on clinico-epidemiological studies and on biological studies to validate and identify new prognostic and predictive factors based on clinico-epidemiological and histological data, genomic host and tumor alterations, tumor microenvironment characteristics, individual immunological profile and functional imaging. In the context of marketing of costly innovative molecules, prospective collection of economic data on t

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
1. Cohort Patients with Resectable stage II or III Inclusion Criteria: Patients diagnosed with resectable stage IIA/IIB/IIC or III melanoma, confirmed by histological exam. Naïve of systemic treatment for resectable stage II or III. Whose metastatic tumoral material can be collected by the Biological Resource Centers (optional criteria). Aged ≥ 18 years. Consenting to participate (signed informed consent). Exclusion Criteria: Patients refusal. Choroid melanoma. Resectable stage 1 melanoma. Stage 4, unresectable primitive or unresectable stage 3 melanoma. Patients under guardianship and under trusteeship. 2. Cohort patients with Unresectable stage III or stage IV (resectable or not) or unresectable primary: Inclusion Criteria: Patients diagnosed with an advanced melanoma, confirmed by histological exam. Unresectable primitive or unresectable stage III or stage IV (resectable or not) melanoma ; or patients treated by neoadjuvant treatment (exceptional) Naïve of systemic treatment for unresectable primitive or unresectable stage III or stage IV (resectable or not) melanoma, except adjuvant treatment. Whose metastatic tumoral material can be collected by the Biological Resource Centers (optional criteria). Aged ≥ 18 years. Consenting to participate (signed informed consent). Exclusion Criteria: Resectable stage 1, 2 or 3 melanoma. Patients refusal. Choroid melanoma. Patients under guardianship and under trusteeship.
💊

What it tests

  • Biological
  • Tissular
  • Quality of life
📍

Where

27 sites
CHU d'Amiens
Amiens, France
CH Annecy Genevois
Annecy, France
CHU de Besançon
Besançon, France
Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Avicennes
Bobigny, France
CHU de Bordeaux Hôpital Haut Levêque
Bordeaux, France
CHU de Bordeaux Hôpital Saint-André
Bordeaux, France
Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Ambroise Paré
Boulogne-Billancourt, France
CHU de Brest
Brest, France

…and 19 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy